Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Vulcan Two Group PLC ( (GB:VUL) ).
Vulcan Two Group reported a £1.22 million pre-tax loss for the period to 31 December 2025, when it remained a pre-revenue cash shell following its £12 million AIM IPO, but ended the year with £9.55 million in cash. Since the year end, it has raised a further £40 million, completed the acquisitions of CloudRx, Webmed and Hyperdrug, and begun integrating these profitable assets into a single scalable platform supported by a new central distribution centre and ERP system.
The acquired businesses generated around £35.7 million in combined unaudited revenue in 2025 and give Vulcan Two a diversified position across B2B and B2C ePharmacy channels, bolstered by key management hires including a new CFO with public markets and M&A experience. Management and the board say the enlarged group is now well placed to capitalise on structural growth in private prescriptions and digital healthcare, with operational investments and a planned unified brand expected to drive efficiencies, service improvements and disciplined acquisition-led expansion.
More about Vulcan Two Group PLC
Vulcan Two Group plc is a UK-based buy-and-build group focused on creating the country’s leading regulated ePharmacy platform. Following the acquisitions of CloudRx, Webmed and Hyperdrug, the company now operates a diversified, profitable platform spanning B2B prescription fulfilment, B2C digital pharmacy services and veterinary prescriptions, targeting the fast-growing private prescription and digital healthcare markets with a high proportion of recurring revenues.
Average Trading Volume: 105,444
Technical Sentiment Signal: Strong Buy
Find detailed analytics on VUL stock on TipRanks’ Stock Analysis page.